Descovy

Emtricitabine 200 mg, tenofovir alafenamide fumarate 25 mg

In combination w/ other antiretrovirals for adults & adolescents (≥12 yr & weighing at least 35 kg) infected w/ HIV-1.

Adult & adolescent ≥12 yr, weighing at least 35 kg In combination w/ dolutegravir, efavirenz, maraviroc, nevirapine, rilpivirine regimen 1 tab once daily.

May be taken with or without food: Swallow whole, do not chew/crush/split.

Hypersensitivity.

Patients w/ chronic hepatitis B or C w/ antiretroviral therapy; co-infected w/ HIV-1 & HCV. Closely monitor patients co-infected w/ HIV & HBV who discontinued Descovy for at least several mth after discontinuation of treatment. Patients w/ significant underlying liver disorders. Monitor patients w/ preexisting liver dysfunction including chronic active hepatitis during treatment. Wt gain & increase in blood lipid & glucose levels may occur during treatment. Mitochondrial dysfunction following exposure in utero. Immune reactivation syndrome. Evaluate any inflammatory symptom & institute treatment when necessary. Antiretroviral-experienced patients w/ HIV-1 harbouring the K65R mutation. Concomitant use w/ a 3rd nucleoside analogue. Closely observe patient for opportunistic infections during treatment. Osteonecrosis. Nephrotoxicity. Patients w/ ESRD on chronic haemodialysis. Concomitant use w/ certain anticonvulsants (eg, carbamazepine, oxcarbazepine, phenobarb & phenytoin), antimycobacterials (eg, rifampicin, rifabutin, rifapentine), boceprevir, St. John's wort (Hypericum perforatum) & HIV PIs other than atazanavir, lopinavir & darunavir, & drugs containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil is not recommended. May impair ability to drive or operate machinery. Pregnancy & lactation.

Nausea. Abnormal dreams; headache, dizziness; diarrhoea, vomiting, abdominal pain, flatulence; rash; fatigue.

Do not administer w/ drugs containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil. Emtricitabine: Conc may be increased w/ drugs that are eliminated by active tubular secretion & drugs that decrease renal function. Tenofovir alafenamide: Decreased absorption w/ drugs that induce P-gp activity (eg, rifampicin, rifabutin, carbamazepine, phenobarb). Increased absorption & plasma conc w/ drugs that inhibit P-gp & BCRP activity (eg, cobicistat, ritonavir, ciclosporin).

Antivirals

J05AR17 - emtricitabine and tenofovir alafenamide ; Belongs to the class of antivirals for treatment of HIV infections, combinations.

S